Panaich Sidakpal, Schreiber Theodore, Grines Cindy
Department of Cardiology, Detroit Medical Center, Michigan, US.
Interv Cardiol. 2014 Aug;9(3):175-179. doi: 10.15420/icr.2014.9.3.175.
Percutaneous coronary intervention (PCI) has undergone major advances including the evolution in stent technology, from bare metal stents (BMS), to their drug eluting counterparts, to the development of bioresorbable scaffolds (BRS). The primary notion of BRS was to facilitate complete vascular healing and restore normal endothelial function following the resorption of stent scaffold while providing equivalent mechanical properties of a metallic drug eluting stents (DES) in the earlier stages. BRS provide attractive physiologic advancements over the existing DES and have shown promising results in initial clinical studies albeit with small sample sizes. Their use has been primarily restricted to patients recruited in clinical trials with limited real-world applicability. Thus, data from larger randomised control trials is awaited. The major objective of this article is to review the evidence on BRS and identify their clinical applicability in current interventional practice.
经皮冠状动脉介入治疗（PCI）取得了重大进展，包括支架技术的演变，从裸金属支架（BMS）到药物洗脱支架，再到生物可吸收支架（BRS）的发展。BRS的主要理念是在支架支架吸收后促进血管完全愈合并恢复正常内皮功能，同时在早期提供与金属药物洗脱支架（DES）相当的机械性能。与现有的DES相比，BRS具有吸引人的生理优势，并且在初始临床研究中显示出有前景的结果，尽管样本量较小。它们的使用主要限于招募到临床试验中的患者，在现实世界中的适用性有限。因此，期待来自更大规模随机对照试验的数据。本文的主要目的是回顾关于BRS的证据，并确定它们在当前介入实践中的临床适用性。
